Takeda Paves The Way For Myovant With Phase III Fibroid Success

 
• By Alexandra Shimmings

Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.

Waves
Japanese Trial First In A Wave For Fibroid Therapy • Source: Shutterstock

More from Clinical Trials

More from R&D